Dejerine Sottas Disease

National Organization for Rare Disorders, Inc.

Skip to the navigation


It is possible that the main title of the report Dejerine Sottas Disease is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.


  • Hereditary Motor Sensory Neuropathy Type III, HSMN Type III
  • Hypertrophic Interstitial Neuritis
  • Hypertrophic Interstitial Neuropathy
  • Hypertrophic Interstitial Radiculoneuropathy
  • Onion-Bulb Neuropathy

Disorder Subdivisions

  • None

General Discussion

Dejerine-Sottas disease is an inherited neurological disorder that progressively affects mobility. Peripheral nerves become enlarged or thickened leading to muscle weakness. Progress of the disorder is irregular and often accompanied by pain, weakness, numbness, and a tingling, prickling or burning sensation in the legs. Many people with Dejerine-Sottas disease continue to lead active lives.

Most neurologists now consider this disorder to be one of 5 types of hereditary motor sensory neuropathy (HMSN) which simply means genetically transmitted disorder of the nerves associated with movement. Dejerine-Sottas disease is one of several that comprise Type III and in which the protective sheath around the long nerves breaks down (demyelination) for unknown reasons exposing and endangering the nerve. The nerves are enlarged due to an accumulation of connective tissue that may present in the form of "onion-bulbs".


Dejerine-Sottas disease tends to begin suddenly, usually between ten and thirty years of age. Tingling, prickling or burning sensations are usually the initial symptoms. Weakness is commonly first noticed in the muscles of the back of the leg. This then spreads to the front leg muscles. Pain, loss of heat sensitivity, absence of reflexes and atrophy of leg muscles are symptoms of Dejerine-Sottas disease.

Patients may eventually develop difficulty in walking. The hand and forearm muscles may become weak in later stages. Mild vision difficulties may also occur.


Dejerine-Sottas disease is inherited as a dominant trait. A recurrent loss of myelin (the protective sheath surrounding nerves) causes this disorder. Scientists do not yet know why the myelin disappears. Human traits including the classic genetic diseases, are the product of the interaction of two genes for that condition, one received from the father and one from the mother. In dominant disorders, a single copy of the disease gene (received from either the mother or father) will be expressed "dominating" the normal gene and resulting in appearance of the disease. The risk of transmitting the disorder from affected parent to offspring is 50% for each pregnancy regardless of the sex of the resulting child.)

Affected Populations

Dejerine-Sottas disease usually begins between ten and thirty years of age. This disorder is thought to affect males and females in equal numbers.

Standard Therapies

Treatment of Dejerine-Sottas disease is symptomatic and supportive. Orthopedic surgery or foot bracing can often be of value to correct or stabilize joints involved with walking. Organizations offering assistance to individuals with vision or mobility deficits and their families can be helpful. Genetic counseling may also be of benefit to families and people with Dejerine-Sottas disease.

Investigational Therapies

Information on current clinical trials is posted on the Internet at All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Tollfree: (800) 411-1222

TTY: (866) 411-1010


For information about clinical trials sponsored by private sources, contact:



Reilly MM, Genetically determined neuropathies. J Neurol. 1998;245:6-13.

Vasilescu C, Hereditary motor and sensory neuropathy. Clinical, genetic and electrophysiological studies. Rom J Neurol Psychiatry. 1993;31:207-219.

Kouvaras G, et al., Hypertrophic peripheral neuropathy (Dejerine-Sottas disease) associated with heart block. Case report presentation and review of the literature. Jpn Heart J. 1990;31:404-410.

Mitchell GW, Response to immunosuppressive therapy in patients with hereditary motor and sensory neuropathy and associated dysimmune neuromuscular disorders. Eur Neurol. 1987;27:188-196.


Charcot-Marie-Tooth disease: Causes -


March of Dimes Birth Defects Foundation

1275 Mamaroneck Avenue

White Plains, NY 10605

Tel: (914)997-4488

Fax: (914)997-4763


Muscular Dystrophy Association

3300 East Sunrise Drive

Tucson, AZ 85718-3208


Tel: (520)529-2000

Fax: (520)529-5300

Tel: (800)572-1717



NIH/National Institute of Neurological Disorders and Stroke

P.O. Box 5801

Bethesda, MD 20824

Tel: (301)496-5751

Fax: (301)402-2186

Tel: (800)352-9424

TDD: (301)468-5981


Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223


Center for Peripheral Neuropathy

University of Chicago

5841 South Maryland Ave, MC 2030

Chicago, IL 60637

Tel: (773)702-5659

Fax: (773)702-5577


Madisons Foundation

PO Box 241956

Los Angeles, CA 90024

Tel: (310)264-0826

Fax: (310)264-4766



Child Neurology Foundation

201 Chicago Ave, #200

Minneapolis, MN 55415


Tel: (952)641-6100

Fax: (952)881-6276

Tel: (877)263-5430



For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see